Antigen-presenting capacity of epidermal cells infected with vaccinia virus recombinants containing the herpes simplex virus glycoprotein D, and protective immunity
- PMID: 2550579
- DOI: 10.1099/0022-1317-70-9-2513
Antigen-presenting capacity of epidermal cells infected with vaccinia virus recombinants containing the herpes simplex virus glycoprotein D, and protective immunity
Abstract
We studied the association of herpes simplex type 1 (HSV-1) glycoprotein D (gD-1) expression in epidermal cells (EC) with virus-specific immunity and protection of mice from fatal HSV-2 challenge. Vaccinia virus recombinants containing gD-1 under the control of an early (VP176) or late (VP254) vaccinia virus promoter were used. Mature gD-1 protein was expressed in VP176-infected EC and they had accessory cell function for HSV-2-induced T cell proliferation of immune lymph node cells (LNC). It was not expressed in VP254-infected EC and they did not act as accessory cells. LNC from VP176- but not VP254-immunized mice proliferated in response to HSV antigen and only VP176-immunized mice had complete long-term protection from HSV-2 challenge.
Similar articles
-
Expression of herpes simplex virus glycoprotein D on antigen presenting cells infected with vaccinia recombinants and protective immunity.Biosci Rep. 1988 Aug;8(4):323-34. doi: 10.1007/BF01115223. Biosci Rep. 1988. PMID: 3263886
-
Regulation of expression of herpes simplex virus (HSV) glycoprotein D in vaccinia recombinants affects their ability to protect from cutaneous HSV-2 disease.J Infect Dis. 1989 Apr;159(4):625-34. doi: 10.1093/infdis/159.4.625. J Infect Dis. 1989. PMID: 2538519
-
Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S924-34. doi: 10.1093/clind/13.supplement_11.s924. Rev Infect Dis. 1991. PMID: 1664130 Review.
-
Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.J Virol. 1988 May;62(5):1530-4. doi: 10.1128/JVI.62.5.1530-1534.1988. J Virol. 1988. PMID: 2833606 Free PMC article.
-
Live vaccinia virus recombinants expressing herpes simplex virus genes.Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S898-903. doi: 10.1093/clind/13.supplement_11.s898. Rev Infect Dis. 1991. PMID: 1664124 Review.
Cited by
-
Expression of Mycobacterium tuberculosis and Mycobacterium leprae proteins by vaccinia virus.Infect Immun. 1990 Dec;58(12):4089-98. doi: 10.1128/iai.58.12.4089-4098.1990. Infect Immun. 1990. PMID: 2123833 Free PMC article.
-
Immune response and cytokine production following immunization with experimental herpes simplex virus 1 (HSV-1) vaccines.Folia Microbiol (Praha). 2008;53(1):73-83. doi: 10.1007/s12223-008-0011-4. Epub 2008 May 15. Folia Microbiol (Praha). 2008. PMID: 18481222
-
Developments in herpes simplex virus vaccines: old problems and new challenges.Folia Microbiol (Praha). 2006;51(2):67-85. doi: 10.1007/BF02932160. Folia Microbiol (Praha). 2006. PMID: 16821715 Review.
-
NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.Infect Immun. 1996 Sep;64(9):3833-44. doi: 10.1128/iai.64.9.3833-3844.1996. Infect Immun. 1996. PMID: 8751936 Free PMC article.
-
Herpes simplex virus type 2 vaccines: new ground for optimism?Clin Diagn Lab Immunol. 2004 May;11(3):437-45. doi: 10.1128/CDLI.11.3.437-445.2004. Clin Diagn Lab Immunol. 2004. PMID: 15138167 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources